Table 3 APOE associations with (A) amyloid status and (B) continuous amyloid burden (centiloids) among Aβ+ clinically unimpaired (CU) individuals. Each column represents a separate regression model. Odds ratios (OR) and their 95% confidence intervals (CI) are provided in (A) and unstandardized betas and their standard errors (SE) are listed in (B)
From: APOE effects on regional tau in preclinical Alzheimer’s disease
A. Predicting amyloid status in 3163 Aβ- and 1323 Aβ+ CUs | B. Predicting continuous amyloid burden in 392 Aβ+ CUs | |||
|---|---|---|---|---|
OR (95% CI), p-value | OR (95% CI), p-value | B (SE), p-value | B (SE), p-value | |
APOE2 | 0.658 (0.526–0.817), p < 0.001 | 0.935 (0.674–1.279), p = 0.679 | −11.815 (4.993), p = 0.019 | −17.310 (7.499), p = 0.022 |
APOE4 | 3.909 (3.445–4.444), p < 0.001 | 4.213 (3.459–5.151), p < 0.001 | 15.321 (2.401), p < 0.001 | 16.411 (3.948), p < 0.001 |
Age (Years) | 1.080 (1.064–1.097), p < 0.001 | 1.092 (1.071–1.114), p < 0.001 | 1.817 (0.302), p < 0.001 | 1.456 (0.434), p < 0.001 |
Sex (F vs. M) | 1.066 (0.925–1.229), p = 0.379 | 1.198 (0.981–1.466), p = 0.078 | 2.638 (2.922), p = 0.367 | 3.317 (4.354), p = 0.447 |
APOE2 * Age | – | 0.946 (0.905–0.989), p = 0.014 | – | 0.565 (1.021), p = 0.580 |
APOE4 * Age | – | 0.991 (0.964–1.019), p = 0.515 | – | 0.534 (0.526), p = 0.310 |
APOE2 * Sex (F vs. M) | – | 0.586 (0.377–0.911), p = 0.018 | – | 9.448 (10.325), p = 0.361 |
APOE4 * Sex (F vs. M) | – | 0.894 (0.692–1.153), p = 0.389 | – | −2.021 (4.983), p = 0.685 |